Learn More
Hammer et al. 1 examined 2817 subjects, including 1325 healthy subjects and patients with schizophrenia (1081), Parkinson disease (263) and affective disorders (148) for the presence of several immunoglobulin subtypes of antibodies against the NR1 subunit of the NMDA receptor (NMDAR). In this large-scale screening, they found that 10.5% of all subjects were(More)
G lutamate-mediated excitotoxicity via N-methyl-d-aspartate receptors (NMdAR) has been a major drug target for the treatment of ischemic stroke over the past 2 decades because excessive NMdAR stimulation is regarded as a lead mechanism mediating stroke-associated brain damage. In contrast to the promising results of extensive preclinical work, however, all(More)
  • 1